PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Reveals whether the business's core operations generate sufficient cash to cover expenses, fund growth, and return capital to shareholders. Sustainable free cash flow is often a key indicator of long-term value creation.
0.03
OCF/share of 0.03 while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss would see if modest cash generation can build a stronger lead.
-0.17
Negative FCF/share while Drug Manufacturers - Specialty & Generic median is -0.01. Seth Klarman would question if the business is too capex-heavy.
756.65%
Capex/OCF ratio of 756.65% while the Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss would confirm if minimal reinvestment is enough for advantage.
0.63
Ratio 0.75–0.9x Drug Manufacturers - Specialty & Generic median of 0.72. John Neff would push for improved working capital or cost management.
61.06%
OCF-to-sales ratio of 61.06% while Drug Manufacturers - Specialty & Generic is zero. Walter Schloss might see a modest advantage in actually generating some cash.